CytoImmune, City of Hope ink CAR-NK cell therapy agreements

By The Science Advisory Board staff writers

April 8, 2021 -- CytoImmune Therapeutics and City of Hope plan to collaborate on a portfolio of chimeric antigen receptor (CAR)-natural killer (NK) cell therapies through global exclusive licensing agreements.

The licenses cover patents held by CytoImmune and are related to ways of generating NK cells and compositions of chimeric receptors for targeting NK cells to tumors, according to CytoImmune and City of Hope. The agreements include a prostate stem cell antigen CAR to treat pancreatic, gastric, bladder, prostate, and some lung cancers; a programmed cell death ligand 1 (PD-L1)+ NK cell for treating lung cancer; and FMS-like tyrosine kinase 3 (FLT3) CAR-NK cell therapy for treating acute myeloid leukemia, they said.

CytoImmune's licenses are based on research conducted by co-founders Jianhua Yu, PhD, and Dr. Michael Caligiuri; Yu is also a professor in the City of Hope Department of Hematology & Hematopoietic Cell Transplantation, and Caligiuri is president of the City of Hope National Medical Center.

City of Hope has treated more than 600 patients since its CAR T research started in the late 1990s, according to CytoImmune and City of Hope.

2nd-gen stem cell-derived CAR gene therapy is more durable, effective against HIV
A novel second-generation chimeric antigen receptor (CAR)-based approach targeting HIV infection using the genetic modification of hematopoietic stem...
FDA approves 1st cell-based gene therapy for multiple myeloma
On March 27 the U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma), the first cell-based gene therapy for treating adult...
City of Hope initiates SARS-CoV-2 vaccine phase I trial
The City of Hope has begun a phase I clinical trial of COH04S1, which is its investigational SARS-CoV-2 vaccine, in healthy volunteers between the ages...
City of Hope licenses CAR T therapy to Chimeric Therapeutics
City of Hope has licensed intellectual property for its chlorotoxin chimeric antigen receptor (CAR) T-cell therapy to Chimeric Therapeutics.
City of Hope sponsors COVID-19 research
City of Hope released details of multiple COVID-19 research projects, including the development of two potential vaccines, new therapies, and better screening...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter